ERBB2 and breast adenocarcinoma: The median DFNA5 CpG4 methylation was 19% [Q1-Q3: 13%–43%] for the breast adenocarcinomas with HER2 amplification, compared to 8% [Q1-Q3: 4%–18%] for the breast adenocarcinomas without HER2 amplification.